Should We Change EU Law to Disallow DNA Patents?

Kathleen Liddell, Johnathon Liddicoat

Research output: Working paper/PreprintDiscussion paper


In the first half of the current decade, the US Supreme Court substantially restricted the patentability of isolated DNA sequence patents and methods of genetic diagnosis through its decisions in Mayo Collaborative Services v Prometheus Laboratories Inc in 2012, and in Association for Molecular Pathology v Myriad Genetics Inc in 2013. A key question for Europeans – and Britons – is whether European law should follow the legal directions in the US: should we also disallow DNA patents? Relatedly, should we disallow genetic diagnostics patents? This paper set the scene for an expert debate on this topic. It focusses on the patentability of DNA sequence patents. The debate was held on 18 November 2016 at the University of Cambridge before a general academic audience.
Original languageEnglish
Publication statusPublished - 28 Jan 2018


  • Intellectual Property
  • Patent Law
  • DNA Patents
  • Gene Patents
  • Patent Eligibility
  • Patentable Subject Matter
  • EU Biotechnology Directive
  • AMP v Myriad


Dive into the research topics of 'Should We Change EU Law to Disallow DNA Patents?'. Together they form a unique fingerprint.

Cite this